menu
    • menu
    [{"orgOrder":0,"company":"AmacaThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"AmacaThera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmacaThera \/ Undisclosed"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AMT-143","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"AmacaThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmacaThera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmacaThera \/ Undisclosed"},{"orgOrder":0,"company":"AmacaThera","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"AMT-143","moa":"Potassium channel | Sodium channel","graph1":"Neurology","graph2":"Phase II","graph3":"AmacaThera","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.23000000000000001,"dosageForm":"Injection, Sustained Release","sponsorNew":"AmacaThera \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"AmacaThera \/ Pacira BioSciences"}]

    Find Clinical Drug Pipeline Developments & Deals by AmacaThera

    Menu

    AmacaThera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Pacira BioSciences

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AmacaThera Signs Global Licensing Deal with Pacira BioSciences for Up To US$230 Million

                            Details : Through the licensing deal for AMT-143, the agreement aims to address post-operative pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $5.0 million

                            November 04, 2025

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Pacira BioSciences

                            Deal Size : $230.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Postsurgical Analgesia After Hernia Repair

                            Details : AMT-143 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hernia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2024

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed

                            AmacaThera

                            Canada arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AmacaThera to Commence Phase 1 Clinical Trial for Non-Opioid, Post-Operative Pain Management

                            Details : AmacaThera has received approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2020

                            Lead Product(s) : AMT-143

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth